Cargando…

Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma

BACKGROUND: The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection. Immune checkpoint inhibitor (ICI) containing regimens are standard of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aeppli, Stefanie, Eboulet, Eric Innocents, Eisen, Tim, Escudier, Bernard, Fischer, Stefanie, Larkin, James, Gruenwald, Viktor, McDermott, David, Oldenburg, Jan, Omlin, Aurelius, Porta, Camillo, Rini, Brian, Schmidinger, Manuela, Sternberg, Cora, Rothermundt, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368485/ https://www.ncbi.nlm.nih.gov/pubmed/32669298 http://dx.doi.org/10.1136/esmoopen-2020-000852

Ejemplares similares

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
por: Aeppli, S., et al.
Publicado: (2021)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Sequence of treatment in locally advanced and metastatic renal cell carcinoma
por: Fischer, Stefanie, et al.
Publicado: (2015)

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
por: Petrausch, Ulf, et al.
Publicado: (2023)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
por: Porta, Camillo, et al.
Publicado: (2017)

804TiP CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
por: Albiges, L., et al.
Publicado: (2020)

Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment
por: Menges, Dominik, et al.
Publicado: (2023)

Radiomics Feature Activation Maps as a New Tool for Signature Interpretability
por: Vuong, Diem, et al.
Publicado: (2020)

In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions
por: Pratsinis, Manolis, et al.
Publicado: (2021)

Emerging Targets in Clear Cell Renal Cell Carcinoma
por: Chen, Yu-Wei, et al.
Publicado: (2022)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

The Tumor Microenvironment of Clear-Cell Ovarian Cancer
por: Devlin, Michael-John, et al.
Publicado: (2022)

Editorial: Immunotherapy in renal cell carcinoma
por: Gruenwald, Viktor, et al.
Publicado: (2022)

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
por: Sternberg, Cora N., et al.
Publicado: (2019)

Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case–control study
por: Omlin, Aurelius, et al.
Publicado: (2013)

Multiple primary tumours: challenges and approaches, a review
por: Vogt, Alexia, et al.
Publicado: (2017)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
por: Mickisch, Gerald HJ, et al.
Publicado: (2011)

Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance
por: Razafinjatovo, Caroline, et al.
Publicado: (2016)

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
por: van der Mijn, Johannes C., et al.
Publicado: (2022)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report
por: Spirig, Christian, et al.
Publicado: (2009)

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma
por: Oudard, Stephane, et al.
Publicado: (2021)

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
por: Saroufim, A, et al.
Publicado: (2014)

STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinoma
por: Marletta, Stefano, et al.
Publicado: (2023)

Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma
por: Han, Seunghun, et al.
Publicado: (2023)

Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma
por: Lucarelli, Giuseppe, et al.
Publicado: (2020)

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
por: Guida, Annalisa, et al.
Publicado: (2020)

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
por: Baird, Richard D., et al.
Publicado: (2021)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
por: Motzer, Robert J, et al.
Publicado: (2021)

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
por: Fischer, Stefanie, et al.
Publicado: (2022)

Clear Cell Acanthoma with Malignant Cytologic Features: A Case Report and Review of the Literature
por: Melson, Gabriella, et al.
Publicado: (2022)

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
por: Rini, Brian I., et al.
Publicado: (2022)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
por: Haanen, J.B.A.G., et al.
Publicado: (2023)

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
por: Dudani, Shaan, et al.
Publicado: (2021)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Oncogenic MicroRNAs Characterization in Clear Cell Renal Cell Carcinoma
por: Petrozza, Vincenzo, et al.
Publicado: (2015)

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
por: McDermott, David F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iqjnio0r82kmlj2bhffsf2kql6